Anglo-Norwegian EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market
Retrieved on:
Tuesday, July 14, 2020
OSLO, Norwayand LONDON, July 14, 2020 /PRNewswire/ --EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company") (Oslo: EXTX-ME), a clinical stage precision medicine company evaluating Acoustic Cluster Therapy (ACT) across multiple therapeutic areas,today announces that its shares have been admitted to trading on Oslo Stock Exchange's Merkur Market under the ticker EXTX-ME with first day of trading 14 July 2020, following the successful completion of a NOK 155 million private placement.
Key Points:
- OSLO, Norwayand LONDON, July 14, 2020 /PRNewswire/ --EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company") (Oslo: EXTX-ME), a clinical stage precision medicine company evaluating Acoustic Cluster Therapy (ACT) across multiple therapeutic areas,today announces that its shares have been admitted to trading on Oslo Stock Exchange's Merkur Market under the ticker EXTX-ME with first day of trading 14 July 2020, following the successful completion of a NOK 155 million private placement.
- The offering attracted strong interest from existing shareholders including Canica, Sundt, Andenaess, Investinor and P53/TDVeen who anchored the financing, and Norwegian family offices and institutions including Nordea.
- The offering was significantly upsized on the back of strong demand.
- EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT).